Category Archives: Clinical Cardiology

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) supported new data, presented at ESC Congress 2020, the annual meeting of the European Society of Cardiology (ESC), held from August 29 - September 1, 2020, adding to the growing body of knowledge on VASCEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events. Continue reading →

Physical activity not only is safe, but necessary for people with heart conditions, according to the authors of new exercise guidelines released this week by the European Society of Cardiology. Continue reading →

Launched in 2019, the VersaCross solution is the world's first all-in-one solution for left-heart access-to-delivery. Continue reading →

Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome (MetS) and stable atherosclerotic cardiovascular (CV) disease, according to the results of a randomized clinical trial published in JAMA Cardiology. Patients (n=27,342) with stable atherosclerotic CV disease and on a statin regimen from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial (FOURIER; ClinicalTrials.gov Identifier: NCT01764633), which was conducted between 2013 and 2016, were stratified according to the National Cholesterol Education Program Adult Treatment Panel III MetS criteria. Patients were randomly assigned to receive the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (subcutaneous injection of 140 mg every 2 weeks or 420 mg per month) or placebo. Continue reading →

A Latest Business Intelligence report released by Market Intellica (MI) with the title Nanomedicine Market Research: Global Status & Forecast by Geography, Type & Application (2016-2026) has abilities to raise as the most important market globally as it has remained to play an amazing role in creating progressive impacts on the entire economy. The World Nanomedicine market report offers energetic visions to conclude and study the market size, market hopes, and competitive backgrounds Continue reading →

August 31, 2020 08:00 ET | Source: Kiniksa Pharmaceuticals, Ltd. HAMILTON, Bermuda, Aug Continue reading →

NEW YORK, Sept. Continue reading →

Sophia Antipolis, France August 31, 2020:Dramatic reductions in the risk of heart attacks in patients with diabetes coincides with major increases in the use of preventive medications. Thats the finding of late breaking research presented today at ESC Congress 2020.1 Our results suggest that when patients are diagnosed with type 2 diabetes, starting medications to prevent cardiovascular disease has a substantial impact on the risk of heart attacks and premature death, said principal investigator Dr. Continue reading →

Sophia Antipolis, France September 1, 2020:Fainting affects one in two people during their lifetime. Those with recurrent episodes are often afraid to socialise or go to work. Today researchers report the first effective therapy. Continue reading →

Munich, Germany (31 August 2020) Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced one-year results of four sub-analyses from the European and global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) programme, a non-interventional safety study evaluating edoxaban treatment in routine clinical practice in > 26,000 patients around the world with atrial fibrillation (AF).1,2,3,4 New 12-month data from the European and global ETNA-AF registries showed rates of bleeding and intracranial haemorrhage (ICH) were considered low by the authors assessment in frail and ageing patients in routine clinical care.1,2,3 Findings, which are part of the largest prospective, non-interventional study programme investigating a single direct oral anticoagulant (DOAC) in patients with non-valvular atrial fibrillation (NVAF) to date, are available virtually at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, taking place 29 August 01 September. In vulnerable populations such as the ageing, frail and those with renal impairment, anticoagulation for stroke prevention is often not prescribed due to the risk of bleeding, despite these patients being among those most at risk for ischaemic events like stroke.5 However, outcomes from ETNA-AF reinforce the effectiveness and safety of edoxaban in these populations.1,2 Ageing and frail patients have been underrepresented in certain AF stroke prevention trials, leaving a lack of evidence to support routine DOAC use in these patients. However, these new data should provide clinicians with some confidence of edoxabans efficacy and safety profile to reduce the risk of stroke for the ageing and frail AF populations, Dr Ameet Bakhai, Consultant Cardiologist & Cardiovascular R&D Director Royal Free London NHS Trust, UK Continue reading →